Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment

Core Insights - Clearmind Medicine Inc. has received patent approval in Hong Kong for its MEAI-based binge behavior regulator program, enhancing its intellectual property portfolio in the psychedelic space [1] - The company now holds 28 granted patents across 18 patent families, with protections in major jurisdictions including the US, Europe, China, India, and Hong Kong [1][2] - MEAI is a novel psychoactive molecule aimed at reducing alcohol consumption and addressing Alcohol Use Disorder, which affects a significant number of individuals [5][6] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, particularly alcohol use disorder [6] - The company plans to continue seeking additional patents and expanding its intellectual property portfolio opportunistically [2] Product Focus - The MEAI compound is designed to regulate binge behavior and may also be effective in treating binge drinking, a serious addiction [4][5] - The flagship treatment targets Alcohol Use Disorder and weight loss, which are prevalent health concerns [5]